Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.

Publication Type:

Journal Article


The New England journal of medicine, Volume 369, Issue 18, p.1715-25 (2013)


2013, Adult, Anti-Retroviral Agents, Cost-Benefit Analysis, Disease Transmission, Infectious, Drug Administration Schedule, Female, Gross Domestic Product, Health Care Costs, HIV Infections, Humans, India, Male, November 2013, South Africa, Vaccine and Infectious Disease Division


The cost-effectiveness of early antiretroviral therapy (ART) in persons infected with human immunodeficiency virus (HIV) in serodiscordant couples is not known. Using a computer simulation of the progression of HIV infection and data from the HIV Prevention Trials Network 052 study, we projected the cost-effectiveness of early ART for such persons.